Entering text into the input field will update the search result below

Premarket Gainers as of 9:05 am

Sep. 05, 2017 9:14 AM ETBy: Gaurav Batavia, SA News Editor12 Comments
  • INSM +121% on the announcement that inhalable amikacin was successful in late-stage study.
  • APOP +31% on announcement that the FDA has designated ApoGraft an Orphan Drug for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.
  • BLPH +14% announced positive top line data from a Phase 2 clinical trial evaluating INOpulse in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.
  • BCRX +11% as HAE candidate BCX7353 successful in mid-stage study.
  • ORMP +11% on successful meeting with FDA for oral insulin.
  • SGYP +5% on $300M debt financing.

Recommended For You